Clinical Trial Update: TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating TAS-102 with or without celecoxib for ctDNA-defined minimal residual disease in colorectal cancer after adjuvant che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING